RECRUITING

Use of Nanodropper vs. Standard Eyedropper in Patients With Glaucoma and Ocular Hypertension

Talk to us

Conditions

Glaucoma, Open-AngleOcular Hypertensionglaucoma

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to evaluate the safety, efficacy, and usability of an eyedrop bottle adaptor that creates smaller eyedrops, Nanodropper, in an open-angle glaucoma/ocular hypertension patient population.

Official Title

Use of Nanodropper vs. Standard Eyedropper in Patients With Glaucoma and Ocular Hypertension

Quick Facts

Study Start:2022-02-28
Study Completion:2025-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05277870

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * ≥18 years old
  2. * Primary open-angle glaucoma (OAG) diagnosis
  3. * Ocular hypertension (OHT) diagnosis
  4. * Corneal thickness \<600 µm
  5. * Use 1-2 IOP-lowering eyedrop medications that are compatible with Nanodropper
  6. * OAG/OHT must be well-controlled (defined as ≥2 IOP measurements collected within 6 months of recruitment that are ≤21 mm Hg with variability of ±3 mm Hg)
  7. * OAG/OHT must be progression-free (as judged by the clinician and based on ≥2 stable OCT and visual field tests collected in the 6 months prior to recruitment)
  1. * Uncontrolled glaucoma (IOP \>21 mmHg)
  2. * Use of \>2 medications for treatment of OAG/OHT
  3. * Use of eyedrop medications that are incompatible with Nanodropper
  4. * OAG/OHT progression (as judged by the clinician within the past 6 months)
  5. * Eye surgery including laser procedures (e.g., SLT, iridotomy) within 6 months of recruitment
  6. * Diagnosis of acute angle-closure glaucoma and/or other retinal diseases

Contacts and Locations

Study Contact

Simona Vuletic
CONTACT
206-520-9728
simona@uw.edu

Principal Investigator

Raghu Mudumbai
PRINCIPAL_INVESTIGATOR
University of Washington

Study Locations (Sites)

University of Washington
Seattle, Washington, 98104
United States

Collaborators and Investigators

Sponsor: University of Washington

  • Raghu Mudumbai, PRINCIPAL_INVESTIGATOR, University of Washington

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-02-28
Study Completion Date2025-06-30

Study Record Updates

Study Start Date2022-02-28
Study Completion Date2025-06-30

Terms related to this study

Keywords Provided by Researchers

  • glaucoma
  • ocular hypertension

Additional Relevant MeSH Terms

  • Glaucoma, Open-Angle
  • Ocular Hypertension